Cargando…

Neoadjuvant modified-FOLFIRINOX followed by surgical resection of both the primary and metastatic tumors of a pancreatic hepatoid carcinoma with synchronous liver metastasis: A case report

RATIONALE: Pancreatic hepatoid carcinoma (PHC) is a rare form of pancreatic malignancy mimicking hepatocellular carcinoma (HCC) in morphology, immunohistochemistry, and behavior. PHC usually has an aggressive clinical course and poor prognosis. Effective treatment strategies are lacking due to poor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Tao, Bai, Xueli, Li, Guogang, Wei, Shumei, Liang, Tingbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671872/ https://www.ncbi.nlm.nih.gov/pubmed/29069039 http://dx.doi.org/10.1097/MD.0000000000008413

Ejemplares similares

Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer
por: Chen, Zhiliang, et al.
Publicado: (2021)

Association of Modified‐FOLFIRINOX‐Regimen‐Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population
por: Li, Xiang, et al.
Publicado: (2018)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Synchronous Resectable Metastatic Colorectal Cancer: Lymph Node Involvement Predicts Poor Outcome
por: Fu, Jianfei, et al.
Publicado: (2015)

Primary hepatoid carcinoma of the ovary: A case report and review of the literature
por: Choi, Won-Ku, et al.
Publicado: (2020)

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019)

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)

Characteristics of lymph node metastasis in resected adenosquamous lung cancer
por: Kong, Min, et al.
Publicado: (2017)

Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma: A Retrospective Cohort Study
por: Paniccia, Alessandro, et al.
Publicado: (2014)

Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis
por: Wu, Ching-Yang, et al.
Publicado: (2015)

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma
por: Tie, Xiaowei, et al.
Publicado: (2022)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
por: Hosein, Peter J, et al.
Publicado: (2012)

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
por: Choi, Young Hoon, et al.
Publicado: (2021)

Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles
por: Lee, Sung Hwan, et al.
Publicado: (2015)

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
por: Wolfe, Adam R., et al.
Publicado: (2020)

Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study
por: Ma, Junxun, et al.
Publicado: (2015)

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
por: Yoo, Changhoon, et al.
Publicado: (2020)

Neoadjuvant chemotherapy does not improve the prognosis and lymph node metastasis rate of locally advanced cervical squamous cell carcinoma: A retrospective cohort study in China
por: Yan, Wenxing, et al.
Publicado: (2019)

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
por: Choi, Jin G., et al.
Publicado: (2018)

Long-term Disease-free Survival Following Combination Multi-visceral and Metastatic Resection with Neoadjuvant FOLFIRINOX for Pancreatic Adenocarcinoma: A Case Report
por: Sodergren, Mikael, et al.
Publicado: (2015)

Applicability of postoperative carcinoembryonic antigen levels in determining post-liver-resection adjuvant chemotherapy regimens for colorectal cancer hepatic metastasis
por: Chiang, Jy-Ming, et al.
Publicado: (2019)

Leptomeningeal metastasis of poorly differentiated uterine cervical adenosquamous carcinoma following reirradiation to metastatic vertebrae: A case report
por: Lu, Yueh-Feng, et al.
Publicado: (2017)

Extended distal pancreatectomy with thoracic wall resection after neoadjuvant FOLFIRINOX: Is there a limit of resection for pancreatic cancer after downstaging?
por: Giuliani, Tommaso, et al.
Publicado: (2020)

Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Janssen, Quisette P., et al.
Publicado: (2021)

Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis
por: Xu, Ya-Ping, et al.
Publicado: (2015)

Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review
por: Gostimir, Mišo, et al.
Publicado: (2016)

Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
por: Hahn, Sarah, et al.
Publicado: (2017)

Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
por: Choi, Yoo Jin, et al.
Publicado: (2021)

Do inflammatory markers predict prognosis in patients with synchronous colorectal cancer?
por: He, Wanbin, et al.
Publicado: (2017)

Neoadjuvant intra-arterial versus intravenous chemotherapy in colorectal cancer
por: Peng, Shu hui, et al.
Publicado: (2021)

Thoracic vertebral metastasis from progressive hepatocellular carcinoma following liver transplantation combined with resection of mesenteric and colonic metastases: A case report
por: Hu, Jingen, et al.
Publicado: (2020)

A Case Report of Male Occult Breast Cancer First Manifesting as Axillary Lymph Node Metastasis With Part of Metastatic Mucinous Carcinoma
por: He, Mengna, et al.
Publicado: (2015)

Sarcoidosis mimicking metastatic progression of pancreatic neuroendocrine tumor: A case report
por: Lolli, Ivan, et al.
Publicado: (2017)

Prognostic significance of a five-factor modified frailty index in patients with gastric cancer undergoing curative-intent resection: A cohort study
por: An, Soomin, et al.
Publicado: (2023)

A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX
por: Yamada, Shuhei, et al.
Publicado: (2023)

Synchronous multiple carcinoma with small intestine and pulmonary neuroendocrine involvement: A case report
por: Shan, Binbin, et al.
Publicado: (2017)

Synchronous double primary lymphoma and thyroid cancer: A single-institution retrospective study
por: Li, Qiuhui, et al.
Publicado: (2021)

Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients With Resectable Pancreatic Ductal Adenocarcinoma
por: Chen, Tao, et al.
Publicado: (2015)

Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer
por: Im, Hyung-Jun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kdjepuvfabkcod1t6o4vvbbrmf